Mode
Text Size
Log in / Sign up

Tissue-resident memory T cells drive disease relapse after biologic and JAK inhibitor discontinuation in atopic dermatitisTissue Memory Cells Linked to Atopic Dermatitis Relapse

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that persistent tissue-resident memory T cells may drive clinical relapse after discontinuing biologics and JAK inhibitors.

This narrative review explores the role of tissue-resident memory (TRM) cells in atopic dermatitis (AD), focusing on their contribution to pathogenesis, chronicity, and relapse. The authors synthesize evidence from experimental, translational, and clinical studies to explain why current treatments often fail to provide permanent remission.

The synthesis indicates that both CD4+ and CD8+ TRM cells persist in skin lesions even after clinical resolution. These cells remain transcriptionally poised for rapid reactivation, providing a mechanism for site-specific relapse. The review notes that while biologics and JAK inhibitors effectively suppress inflammatory pathways, they do not eliminate the underlying pathogenic tissue memory.

Emerging data suggest that specific interventions targeting costimulatory pathways or survival signals may partially influence immune memory to prolong disease control in some patients. However, as a narrative review of diverse study types, the evidence is primarily mechanistic and translational. The authors note that while TRM cells provide a clear explanation for treatment resistance, the specific outcomes of new interventions targeting these cells are not yet confirmed.

How this fits prior evidence

This narrative review addresses a gap in understanding why patients with atopic dermatitis often experience relapse after stopping biologics or JAK inhibitors. While previous coverage noted that upadacitinib 30 mg is a high-efficacy option for moderate-to-severe atopic dermatitis and that JAK inhibitors are associated with higher hepatitis B virus reactivation rates than IL-12/23 or IL-17 inhibitors, this review provides the underlying immunological mechanism for treatment resistance. It explains how persistent TRM cells contribute to the limitations of current systemic therapies.

This review looks at the role of tissue-resident memory T (TRM) cells in people with atopic dermatitis. These are specific immune cells that stay in the skin even after a flare-up seems to have cleared. The study found that both CD4+ and CD8+ types of these cells remain active in the skin, making it easier for the condition to return quickly.

When patients stop using current treatments like biologics or JAK inhibitors, their symptoms often come back. This happens because these medications manage inflammation but do not remove the underlying immune memory stored in the tissue. The review suggests that these memory cells are a key reason why some people experience repeated cycles of flare-ups and remission.

While current treatments are effective at controlling symptoms, they may not provide a permanent fix because the skin's memory remains. Some newer approaches are being explored to target these specific pathways to help patients stay in remission longer. Because this is an early review of experimental data, it does not offer new clinical guidelines yet.

What this means for you:
Persistent immune cells in the skin may cause atopic dermatitis to return after treatment stops.

Common questions

Why does my eczema come back after I stop medication?

The review suggests that certain immune cells, called tissue-resident memory T cells, stay in the skin even after symptoms clear. While medications like biologics and JAK inhibitors reduce inflammation, they do not eliminate these memory cells. Because these cells remain active, the condition can flare up again once treatment is stopped.

What are TRM cells and how do they affect my skin?

TRM cells are immune cells that live in specific tissues like the skin. In people with atopic dermatitis, these cells stay in the skin and remain ready to react quickly. This presence of memory cells provides a reason why the condition can become chronic or cause relapses after treatment.

Are there new ways to keep my skin clear longer?

The review notes that some emerging data suggest specific interventions might influence immune memory and help some patients stay in control for longer. However, these are still experimental ideas. You should talk to your doctor about the best way to manage your specific treatment plan.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease in which disease flares frequently recur at previously affected anatomical sites. This distinctive clinical pattern suggests the presence of residual inflammation and long-lasting local immune memory that persists beyond apparent clinical remission. To synthesize current evidence on the role of tissue-resident memory T (TRM) cells in the pathogenesis, chronicity, and relapse of AD, and to discuss how TRM biology may explain disease recurrence after treatment withdrawal and inform future therapeutic strategies. Narrative review of experimental, translational, and clinical studies addressing TRM differentiation, persistence, metabolic and epigenetic programming, clonal stability, microenvironmental crosstalk, and treatment-related modulation in AD and related chronic dermatoses. TRM are long-lived, non-circulating T cells retained in the skin through adhesion molecules, survival cytokines, metabolic adaptation, and stable epigenetic programs. In AD, both CD4+ and CD8+ TRM persist in lesional and clinically resolved skin and remain transcriptionally poised for rapid reactivation. Clinical studies consistently demonstrate disease relapse after discontinuation of biologics and JAK inhibitors, supporting the concept that current therapies suppress inflammatory pathways without eliminating pathogenic tissue memory. Emerging data suggest that selected interventions, including modulation of costimulatory pathways and survival signals, may partially influence immune memory and prolong disease control in subsets of patients. TRM constitute a central cellular substrate of residual disease memory in AD and provide a mechanistic explanation for site-specific relapse and treatment resistance. Therapeutic strategies that selectively modulate pathogenic TRM and their supporting microenvironment, while preserving protective barrier immunity, may be required to achieve durable remission.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.